Therefore, interventions targeting IL-36α and its receptor, IL-36R, may represent potential therapeutic targets for treating AKI, offering a new avenue for mitigating inflammatory responses (Fig. 2A and Fig. S1). This evidence concerns the gene IL1RL2 and acute kidney injury.